Baloxavir marboxil(trade name Xofluza) is a novel oral anti-influenza virus drug that is a selective inhibitor of the influenza cap-dependent endonuclease. A single oral dose of baloxavir marboxil in tablet form improves medication adherence and rapidly reduces viral titres in paediatric influenza patients.

In a recent study, by investigating the frequency of outpatient pharmacy revisits for baloxavir marboxil compared with the frequency of paediatric influenza patients on neuraminidase inhibitors, it was found that the main medications prescribed were baloxavir (149), oseltamivir (161) and raninavir (162), with only a minority of patients using paramivir (2) or zanamivir (1). Statistical analysis showed that paediatric patients taking baloxavir (Marboxil), oseltamivir and raninavir had a lower rate of follow-up than those taking oseltamivir^[1].

Reference:

[1] NORIKOSHIYU. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.[J]. Biological & pharmaceutical bulletin, 2020, 43 12: 1960-1965. DOI:10.1248/bpb.b20-00543.